27284493|t|Sensitization to the motor stimulant effects of 3,4-methylenedioxypyrovalerone (MDPV) and cross-sensitization to methamphetamine in rats
27284493|a|In recent years, there has been a dramatic increase in abuse of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV), often in combination with other illicit stimulants. We sought to determine if repeated exposure to MDPV would produce sensitization to the motor stimulant effects of the drug, and whether cross-sensitization would develop with the stimulant effects of methamphetamine (METH). Male Sprague-Dawley rats were administered MDPV (1 or 5 mg/kg) or saline once daily for 5 days at 24 hour intervals, or were administered MDPV (1 mg/kg) or saline once daily for 5 days at 48 hour intervals. For cross-sensitization experiments, rats were administered METH (1 mg/kg) or MDPV (1 or 5 mg/kg) once daily for 5 days at 48 hour intervals, and following a 5 day incubation period, were given an acute challenge injection of either MDPV (0.5 mg/kg) or METH (0.5 mg/kg), respectively. Rats repeatedly administered MDPV (1 mg/kg) every 48 hours, but not every 24 hours, demonstrated increased motor activity when given either a subsequent challenge of MDPV (0.5 mg/kg i.p.) or METH (0.5 mg/kg), indicating the development of behavioral sensitization and cross-sensitization, respectively. Moreover, rats repeatedly administered METH (1 mg/kg) every 48 hours did not exhibit cross-sensitization to the motor stimulating effects of a subsequent challenge with MDPV (0.5 mg/kg). These results suggest that specific patterns of MDPV administration may lead to lasting changes in behavioral responses to subsequent METH exposure.
27284493	0	13	Sensitization	T040	C1325847
27284493	21	26	motor	T025	C0026609
27284493	27	36	stimulant	T121	C0304402
27284493	37	44	effects	T080	C1280500
27284493	48	78	3,4-methylenedioxypyrovalerone	T109	C2974592
27284493	80	84	MDPV	T109	C2974592
27284493	90	109	cross-sensitization	T040	C1325847
27284493	113	128	methamphetamine	T109,T131	C0025611
27284493	132	136	rats	T015	C0086893
27284493	147	152	years	T079	C0439234
27284493	180	188	increase	T081	C0205217
27284493	192	197	abuse	T048	C0013146
27284493	205	224	synthetic cathinone	T109,T121	C0054876
27284493	225	255	3,4-methylenedioxypyrovalerone	T109	C2974592
27284493	257	261	MDPV	T109	C2974592
27284493	273	284	combination	T080	C0205195
27284493	296	303	illicit	T169	C0332266
27284493	304	314	stimulants	T121	C0304402
27284493	342	350	repeated	T169	C0205341
27284493	351	362	exposure to	T080	C0332157
27284493	363	367	MDPV	T109	C2974592
27284493	382	395	sensitization	T040	C1325847
27284493	403	408	motor	T025	C0026609
27284493	409	418	stimulant	T121	C0304402
27284493	419	426	effects	T080	C1280500
27284493	434	438	drug	T121	C0013227
27284493	452	471	cross-sensitization	T040	C1325847
27284493	478	485	develop	T169	C1527148
27284493	495	504	stimulant	T121	C0304402
27284493	505	512	effects	T080	C1280500
27284493	516	531	methamphetamine	T109,T131	C0025611
27284493	533	537	METH	T109,T131	C0025611
27284493	540	544	Male	T032	C0086582
27284493	545	564	Sprague-Dawley rats	T015	C0034715
27284493	570	582	administered	T081	C0001555
27284493	583	587	MDPV	T109	C2974592
27284493	606	612	saline	T167	C0036082
27284493	613	623	once daily	T079	C0556983
27284493	630	634	days	T079	C0439228
27284493	641	645	hour	T079	C0439227
27284493	646	655	intervals	T079	C1272706
27284493	665	677	administered	T081	C0001555
27284493	678	682	MDPV	T109	C2974592
27284493	696	702	saline	T167	C0036082
27284493	703	713	once daily	T079	C0556983
27284493	720	724	days	T079	C0439228
27284493	731	735	hour	T079	C0439227
27284493	736	745	intervals	T079	C1272706
27284493	751	770	cross-sensitization	T040	C1325847
27284493	771	782	experiments	T062	C0205664
27284493	784	788	rats	T015	C0034715
27284493	794	806	administered	T081	C0001555
27284493	807	811	METH	T109,T131	C0025611
27284493	825	829	MDPV	T109	C2974592
27284493	845	855	once daily	T079	C0556983
27284493	862	866	days	T079	C0439228
27284493	873	877	hour	T079	C0439227
27284493	878	887	intervals	T079	C1272706
27284493	907	910	day	T079	C0439228
27284493	911	928	incubation period	T033	C1320226
27284493	960	969	injection	T122	C1272883
27284493	980	984	MDPV	T109	C2974592
27284493	1000	1004	METH	T109,T131	C0025611
27284493	1032	1036	Rats	T015	C0034715
27284493	1037	1047	repeatedly	T169	C0205341
27284493	1048	1060	administered	T081	C0001555
27284493	1061	1065	MDPV	T109	C2974592
27284493	1085	1090	hours	T079	C0439227
27284493	1109	1114	hours	T079	C0439227
27284493	1129	1138	increased	T081	C0205217
27284493	1139	1153	motor activity	T033	C0243095
27284493	1198	1202	MDPV	T109	C2974592
27284493	1223	1227	METH	T109,T131	C0025611
27284493	1256	1281	development of behavioral	T040	C2825534
27284493	1282	1295	sensitization	T040	C1325847
27284493	1300	1319	cross-sensitization	T040	C1325847
27284493	1345	1349	rats	T015	C0034715
27284493	1361	1373	administered	T081	C0001555
27284493	1374	1378	METH	T109,T131	C0025611
27284493	1398	1403	hours	T079	C0439227
27284493	1420	1439	cross-sensitization	T040	C1325847
27284493	1447	1452	motor	T025	C0026609
27284493	1453	1464	stimulating	T070	C1948023
27284493	1465	1472	effects	T080	C1280500
27284493	1504	1508	MDPV	T109	C2974592
27284493	1528	1535	results	T169	C1274040
27284493	1558	1566	patterns	T082	C0449774
27284493	1570	1574	MDPV	T109	C2974592
27284493	1575	1589	administration	T081	C0001555
27284493	1621	1631	behavioral	T053	C0004927
27284493	1632	1641	responses	T032	C0871261
27284493	1656	1660	METH	T109,T131	C0025611
27284493	1661	1669	exposure	T080	C0332157